TABLE 4.

Summary of properties of the growth-adaptive E2 variants^a

Virus	H77 residue	Fold decrease in RNA-to-TCID50 ratiob	Fold change in EC50c					Antibody dose responsed (% resistant)
			H77.39*	HC84.26*	CD81-LEL*	Anti-CD81**	Anti-CLDN1**	Anti-SR-BI	SR-BIKO
Q412R	Q412	1.7	19	8.4	2.1	2.2	2.0	82	58
T416R	T416	2.3	63	6.5	5.5	2.8	1.4	72	57
S449P	S449	2.0	46	11	1.5	0.91	1.9	100	59
T563V	T561	3.3	26	9.7	6.2	1.4	1.3	55	55
A579R	(N577)	3.8	2.8	1.0	1.1	2.6	1.5	34	33
L619T	L615	2.6	28	6.0	10	3.3	1.7	100	61
V626S	I622	1.5	4.9	2.6	1.6	2.6	2.7	57	44
K632T	K628	1.2	1.2	1.7	0.44	2.1	4.4	36	44
L644I	L640	1.3	3.8	4.5	1.7	1.2	2.7	53	58

^aA summary of the properties of the mutants identified in this study.

^bFold decrease relative to parent is listed for the RNA-to-TCID₅₀ ratio.

^cThe fold change in EC₅₀ (increase or decrease) is listed for all dose-response inhibition assays. *, fold decrease; **, fold increase.

^dFor the SR-BI antibody dose response or infection of SR-BI^KO cells, the percentage of virus resistant to SR-BI blockade or deletion is listed.